Akari Therapeutics PLC (AKTX)
2.10
-0.13
(-5.83%)
USD |
NASDAQ |
Nov 15, 13:33
Akari Therapeutics Net Income (TTM): -16.12M for June 30, 2024
Net Income (TTM) Chart
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | -16.12M |
| March 31, 2024 | -14.24M |
| June 30, 2023 | -13.86M |
| March 31, 2023 | -15.64M |
| June 30, 2022 | -18.10M |
| March 31, 2022 | -16.76M |
| December 31, 2021 | -17.42M |
| September 30, 2021 | -18.45M |
| June 30, 2021 | -16.08M |
| March 31, 2021 | -19.17M |
| December 31, 2020 | -17.08M |
| September 30, 2020 | -17.89M |
| June 30, 2020 | -21.37M |
| March 31, 2020 | -18.05M |
| December 31, 2019 | -16.85M |
| September 30, 2019 | -16.77M |
| June 30, 2019 | -17.80M |
| March 31, 2019 | -21.71M |
| Date | Value |
|---|---|
| December 31, 2018 | -20.50M |
| September 30, 2018 | -25.07M |
| June 30, 2018 | -31.86M |
| March 31, 2018 | -24.15M |
| December 31, 2017 | -35.40M |
| September 30, 2017 | -31.57M |
| June 30, 2017 | -21.61M |
| March 31, 2017 | -27.74M |
| December 31, 2016 | -18.14M |
| September 30, 2016 | -3.383M |
| June 30, 2016 | -51.70M |
| March 31, 2016 | -46.59M |
| December 31, 2015 | -45.30M |
| September 30, 2015 | -52.89M |
| June 30, 2015 | -4.374M |
| March 31, 2015 | -5.263M |
| December 31, 2014 | -5.306M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (TTM) Range, Past 5 Years
-21.37M
Minimum
Jun 2020
-13.86M
Maximum
Jun 2023
-17.14M
Average
-17.08M
Median
Dec 2020
Net Income (TTM) Benchmarks
| Adaptimmune Therapeutics PLC | -72.50M |
| Biodexa Pharmaceuticals PLC | -8.534M |
| NuCana PLC | -35.48M |
| Autolus Therapeutics PLC | -233.98M |
| Genfit SA | -- |